Novo Nordisk A/S vs Banco Santander, S.A.: Strategic Comparison

This in-depth comparison examines Novo Nordisk A/S and Banco Santander, S.A. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novo Nordisk A/S on its own, evaluating Banco Santander, S.A., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novo Nordisk A/S and Banco Santander, S.A. is widest.

On the headline numbers, Novo Nordisk A/S reports annual revenue of $46.0B against $62.4B for Banco Santander, S.A., while their respective market capitalizations stand at $550.0B and $195.3B. Novo Nordisk A/S is headquartered in Denmark and Banco Santander, S.A. operates from Spain, and those different home markets shape how each company competes.

Novo Nordisk A/S: Novo Nordisk A/S is a public company listed on NYSE under ticker NVO. Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.

Banco Santander, S.A.: Santander is best understood as a collection of local banks being rewired into a more common operating platform. The local franchises supply deposits, credit relationships, and regulatory knowledge; the global layer supplies technology, cards, payments, risk tools, and management discipline. If ONE Santander keeps lowering cost-to-income while customer growth continues, the bank can turn complexity into an advantage instead of a drag.

Novo Nordisk A/S and Banco Santander, S.A. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novo Nordisk A/S and Banco Santander, S.A..

Novo Nordisk A/S business model: Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.

Banco Santander, S.A. business model: Santander makes money from net interest income on loans and securities, fees from payments and account activity, wealth and insurance commissions, consumer finance, cards, auto lending, and corporate and investment banking services. Its deposit base supplies relatively low-cost funding, while its geographic spread lets the group allocate capital toward higher-return markets when individual regions slow.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novo Nordisk A/S stack up against those of Banco Santander, S.A..

Novo Nordisk A/S competitive advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.

Banco Santander, S.A. competitive advantage: Santander's edge is the combination of local banking scale and global operating reuse. Few banks have comparable retail reach across Iberia, the United Kingdom, Brazil, Mexico, Chile, and the United States while also building shared technology, payments, cards, and risk platforms. That scale supports lower unit costs and broader customer data than a single-market bank can usually achieve.

Future prospects matter as much as current results. The growth strategies below explain how Novo Nordisk A/S and Banco Santander, S.A. each plan to expand from here.

Novo Nordisk A/S growth strategy: Novo Nordisk A/S's growth strategy centers on this advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.

Banco Santander, S.A. growth strategy: The growth plan is to add customers in core retail markets, push more activity through global platforms, expand fee income in wealth and payments, and concentrate capital where Santander has either leading local scale or strong cross-border network effects. Management is also returning excess capital through dividends and buybacks while keeping CET1 above target.

A closer look at the financial trajectory of Novo Nordisk A/S and Banco Santander, S.A. rounds out the comparison.

Novo Nordisk A/S: Novo Nordisk A/S reported FY2025 revenue of DKK 309.064B (about $46.0B) and net income of DKK 102.434B (about $15.2B).

Banco Santander, S.A.: Santander uses total income as the closest banking equivalent to revenue. In 2025, total income was EUR 62.390 billion, net fee income reached EUR 13.661 billion, attributable profit was EUR 14.101 billion, RoTE was 16.3%, and CET1 was 13.5%. The market capitalization field is shown in USD and reflects a point-in-time public-market value, not book value or regulatory capital.